Relapsing-Remitting / Secondary Progressive Multiple Sclerosis
If you, or a loved one, are suffering from multiple sclerosis (MS), there is hope. Medical and non-profit organizations are working tirelessly to find treatments and a cure. Part of the process of discovering effective treatments for MS are clinical trials. These research studies and clinical trials are separated into phases, and are offered to patients with multiple sclerosis after pre-clinical trials and early phase studies are completed.
A MS clinical trial offers patients the opportunity to receive care from some of the nation’s leading neurologists, and includes treatment and continued monitoring at no cost to the patient, with expenses for time and travel potentially reimbursed as well.
Neurologist Leading the Study
Ajay Gupta, M.D.
The Neurological Research Center at the Fort Wayne Neurological Center is currently enrolling for a clinical study to assess the effectiveness of a new treatment option for patients with active relapse multiple sclerosis.
If you are currently suffering from RMS and being treated with DMF, please contact our office or fill out the form below to see if you are eligible for this study. To learn more about participating in a study at the neurological research center read our patient FAQ page or contact us with additional questions.
You may qualify for the Multiple Sclerosis study if you must meet the following criteria.
- Condition: Relapsing-remitting Multiple Sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with superimposed relapses.
- Age: 18-55
- Gender: Male or Female
- Signed informed consent prior to initiation of any study-mandated procedure.
- Women of childbearing potential must have a negative pregnancy test and use reliable methods of contraception.
- Presenting with a diagnosis of MS as defined by the revised (2010) McDonald Diagnostic Criteria for MS with relapsing course from onset (i.e., relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) with superimposed relapses).
- Ongoing treatment with Dimethyl Fumarate for at least 6 months prior to screening
- Active disease after at least 3 months of Dimethyl Fumarate treatment (DMF) treatment.
- Ambulatory and with an EDSS score between 0 and 6.0 (inclusive).
If the following apply, you may NOT qualify for this research study.
- Lactating or pregnant women and women intending to become pregnant during the study.
- Presenting with a diagnosis of MS with progressive course from onset (i.e., primary progressive MS or progressive relapsing MS).
- Evidence of a relapse of MS with onset within 30 days prior to baseline EDSS assessment.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.